• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肉瘤的分子发病机制及诊断、预后和预测性分子标志物

Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma.

作者信息

Mariño-Enríquez Adrián, Bovée Judith V M G

机构信息

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.

Department of Pathology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333 ZA, The Netherlands.

出版信息

Surg Pathol Clin. 2016 Sep;9(3):457-73. doi: 10.1016/j.path.2016.04.009.

DOI:10.1016/j.path.2016.04.009
PMID:27523972
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4988391/
Abstract

Sarcomas are infrequent mesenchymal neoplasms characterized by notable morphological and molecular heterogeneity. Molecular studies in sarcoma provide refinements to morphologic classification, and contribute diagnostic information (frequently), prognostic stratification (rarely) and predict therapeutic response (occasionally). Herein, we summarize the major molecular mechanisms underlying sarcoma pathogenesis and present clinically useful diagnostic, prognostic and predictive molecular markers for sarcoma. Five major molecular alterations are discussed, illustrated with representative sarcoma types, including 1. the presence of chimeric transcription factors, in vascular tumors; 2. abnormal kinase signaling, in gastrointestinal stromal tumor; 3. epigenetic deregulation, in chondrosarcoma, chondroblastoma, and other tumors; 4. deregulated cell survival and proliferation, due to focal copy number alterations, in dedifferentiated liposarcoma; 5. extreme genomic instability, in conventional osteosarcoma as a representative example of sarcomas with highly complex karyotype.

摘要

肉瘤是罕见的间充质肿瘤,具有显著的形态学和分子异质性。肉瘤的分子研究为形态学分类提供了细化,并(经常)提供诊断信息、(很少)进行预后分层以及(偶尔)预测治疗反应。在此,我们总结了肉瘤发病机制的主要分子机制,并介绍了临床上有用的肉瘤诊断、预后和预测分子标志物。讨论了五种主要的分子改变,并以代表性的肉瘤类型进行说明,包括:1. 血管肿瘤中嵌合转录因子的存在;2. 胃肠道间质瘤中异常的激酶信号传导;3. 软骨肉瘤、软骨母细胞瘤和其他肿瘤中的表观遗传失调;4. 去分化脂肪肉瘤中由于局灶性拷贝数改变导致的细胞存活和增殖失调;5. 传统骨肉瘤中极端的基因组不稳定性,作为具有高度复杂核型的肉瘤的代表例子。

相似文献

1
Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma.肉瘤的分子发病机制及诊断、预后和预测性分子标志物
Surg Pathol Clin. 2016 Sep;9(3):457-73. doi: 10.1016/j.path.2016.04.009.
2
GLI1 Immunohistochemistry Distinguishes Mesenchymal Neoplasms With GLI1 Alterations From Morphologic Mimics.GLI1免疫组化可将伴有GLI1改变的间叶性肿瘤与形态学相似的肿瘤区分开来。
Am J Surg Pathol. 2023 Apr 1;47(4):453-460. doi: 10.1097/PAS.0000000000002018. Epub 2023 Jan 23.
3
Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.177例软组织肉瘤的诊断和预后基因表达特征:缺氧诱导转录谱表明转移潜能。
BMC Genomics. 2007 Mar 14;8:73. doi: 10.1186/1471-2164-8-73.
4
Advances in the Molecular Analysis of Soft Tissue Tumors and Clinical Implications.软组织肿瘤的分子分析进展及临床意义
Surg Pathol Clin. 2015 Sep;8(3):525-37. doi: 10.1016/j.path.2015.06.001.
5
Pleomorphic Sarcomas: The State of the Art.多形性肉瘤:最新进展
Surg Pathol Clin. 2019 Mar;12(1):63-105. doi: 10.1016/j.path.2018.10.004. Epub 2018 Dec 17.
6
Contemporary Sarcoma Diagnosis, Genetics, and Genomics.当代肉瘤的诊断、遗传学与基因组学。
J Clin Oncol. 2018 Jan 10;36(2):101-110. doi: 10.1200/JCO.2017.74.9374. Epub 2017 Dec 8.
7
[Detection of chromosomal abnormalities in soft tissue sarcomas: which sarcomas? Which abnormalities? How? Why?].[软组织肉瘤中染色体异常的检测:哪些肉瘤?哪些异常?如何检测?为何检测?]
Bull Cancer. 2007 Sep;94(9):781-92.
8
Molecular diagnostics in soft tissue sarcomas and gastrointestinal stromal tumors.软组织肉瘤和胃肠道间质瘤的分子诊断
J Surg Oncol. 2015 Apr;111(5):520-31. doi: 10.1002/jso.23882. Epub 2015 Mar 13.
9
[Molecular biology for sarcoma: useful or necessary?].[肉瘤的分子生物学:有用还是必要?]
Ann Pathol. 2015 Jan;35(1):107-13. doi: 10.1016/j.annpat.2014.11.004. Epub 2014 Dec 20.
10
Immunohistochemical correlates of recurrent genetic alterations in sarcomas.肉瘤中复发性遗传改变的免疫组化相关性。
Genes Chromosomes Cancer. 2019 Feb;58(2):111-123. doi: 10.1002/gcc.22700. Epub 2018 Dec 19.

引用本文的文献

1
A Comprehensive Review of Cardiac Tumors: Imaging, Pathology, Treatment, and Challenges in the Third Millennium.心脏肿瘤综合综述:第三个千年中的影像学、病理学、治疗及挑战
Diagnostics (Basel). 2025 May 30;15(11):1390. doi: 10.3390/diagnostics15111390.
2
Enhancing precision in sarcoma diagnosis: nCounter fusion panel implementation in a middle-income country.提高肉瘤诊断的精准度:在中等收入国家实施nCounter融合检测平台
Ther Adv Med Oncol. 2025 Mar 14;17:17588359251318159. doi: 10.1177/17588359251318159. eCollection 2025.
3
Pan-TRK positive uterine sarcoma in immunohistochemistry without neurotrophic tyrosine receptor kinase gene fusions: A case report.

本文引用的文献

1
Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations.血管肉瘤中CIC基因异常的复发:一项对120例病例的分子研究,同时调查PLCG1、KDR、MYC和FLT4基因改变
Am J Surg Pathol. 2016 May;40(5):645-55. doi: 10.1097/PAS.0000000000000582.
2
Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.琥珀酸脱氢酶(SDH)和延胡索酸水合酶(FH)的失活导致副神经节瘤/嗜铬细胞瘤和平滑肌肉瘤中5-羟甲基胞嘧啶(5hmC)缺失及组蛋白H3赖氨酸9三甲基化(H3K9me3)增加。
Oncotarget. 2015 Nov 17;6(36):38777-88. doi: 10.18632/oncotarget.6091.
3
免疫组化检测呈泛TRK阳性但无神经营养性酪氨酸受体激酶基因融合的子宫肉瘤:一例报告
World J Clin Cases. 2025 Jan 16;13(2):96876. doi: 10.12998/wjcc.v13.i2.96876.
4
Evaluating Circulating Biomarkers for Diagnosis, Prognosis, and Tumor Monitoring in Pediatric Sarcomas: Recent Advances and Future Directions.评估儿童肉瘤的诊断、预后和肿瘤监测的循环生物标志物:最新进展和未来方向。
Biomolecules. 2024 Oct 16;14(10):1306. doi: 10.3390/biom14101306.
5
Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection.用于靶向治疗选择的脂肪肉瘤中的遗传、表观遗传和转录组改变
Cancers (Basel). 2024 Jan 8;16(2):271. doi: 10.3390/cancers16020271.
6
Neoadjuvant Therapies Do Not Reduce Epidermal Growth Factor Receptor (EGFR) Expression or EGFR-Targeted Fluorescence in a Murine Model of Soft-Tissue Sarcomas.新辅助治疗不会降低软组织肉瘤小鼠模型中的表皮生长因子受体 (EGFR) 表达或 EGFR 靶向荧光。
Mol Imaging Biol. 2024 Apr;26(2):272-283. doi: 10.1007/s11307-023-01884-9. Epub 2023 Dec 27.
7
Predictive Biomarkers of Pathological Response to Neoadjuvant Chemoradiotherapy for Locally Advanced Soft Tissue Sarcomas.局部晚期软组织肉瘤新辅助放化疗病理反应的预测生物标志物
Cancers (Basel). 2023 May 29;15(11):2960. doi: 10.3390/cancers15112960.
8
Accuracy of core needle biopsy for histologic diagnosis of soft tissue sarcoma.软组织肉瘤组织学诊断中核心针活检的准确性。
Sci Rep. 2022 Feb 3;12(1):1886. doi: 10.1038/s41598-022-05752-4.
9
Pyroptosis-Related Gene Signature Is a Novel Prognostic Biomarker for Sarcoma Patients.焦亡相关基因特征是肉瘤患者的一种新的预后生物标志物。
Dis Markers. 2021 Dec 3;2021:9919842. doi: 10.1155/2021/9919842. eCollection 2021.
10
Over-methylation of Histone H3 Lysines Is a Common Molecular Change Among the Three Major Types of Soft-tissue Sarcoma in Patient-derived Xenograft (PDX) Mouse Models.组蛋白 H3 赖氨酸过度甲基化是患者来源异种移植(PDX)小鼠模型中三种主要软组织肉瘤的常见分子改变。
Cancer Genomics Proteomics. 2021 Nov-Dec;18(6):715-721. doi: 10.21873/cgp.20292.
Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.
H3F3A和H3F3B的突变分析作为骨巨细胞瘤和软骨母细胞瘤的诊断工具
Am J Surg Pathol. 2015 Nov;39(11):1576-83. doi: 10.1097/PAS.0000000000000512.
4
Nuclear Expression of CAMTA1 Distinguishes Epithelioid Hemangioendothelioma From Histologic Mimics.CAMTA1的核表达可将上皮样血管内皮瘤与组织学模仿物区分开来。
Am J Surg Pathol. 2016 Jan;40(1):94-102. doi: 10.1097/PAS.0000000000000511.
5
DOG1 expression in giant-cell-containing bone tumours.DOG1在含巨细胞骨肿瘤中的表达。
Histopathology. 2016 May;68(6):942-5. doi: 10.1111/his.12873. Epub 2015 Dec 21.
6
Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.用小分子突变型异柠檬酸脱氢酶1(IDH1)抑制剂治疗可抑制人软骨肉瘤细胞的致瘤活性并减少致癌代谢物2-羟基戊二酸的产生。
PLoS One. 2015 Sep 14;10(9):e0133813. doi: 10.1371/journal.pone.0133813. eCollection 2015.
7
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas.SMARCA4 失活定义了一组未分化的胸恶性肿瘤,这些肿瘤在转录上与 BAF 缺陷型肉瘤相关。
Nat Genet. 2015 Oct;47(10):1200-5. doi: 10.1038/ng.3399. Epub 2015 Sep 7.
8
New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype.肉瘤的新策略:将基因组与免疫疗法方法与分子亚型联系起来。
Clin Cancer Res. 2015 Nov 1;21(21):4753-9. doi: 10.1158/1078-0432.CCR-15-0831. Epub 2015 Sep 1.
9
Fusion events lead to truncation of FOS in epithelioid hemangioma of bone.融合事件导致骨上皮样血管瘤中FOS的截短。
Genes Chromosomes Cancer. 2015 Sep;54(9):565-74. doi: 10.1002/gcc.22269. Epub 2015 Jul 14.
10
Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes.突变型异柠檬酸脱氢酶1(IDH1)与软骨和骨相关基因的基因特异性组蛋白修饰相关,失调间充质干细胞的分化。
PLoS One. 2015 Jul 10;10(7):e0131998. doi: 10.1371/journal.pone.0131998. eCollection 2015.